左氧氟沙星三联治疗根除幽门螺旋杆菌临床疗效观察

Clinical Efficacy of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

目的观察以左氧氟沙星为基础的三联疗法根除幽门螺旋杆菌的疗效。方法选择202例幽门螺旋杆菌感染患者,随机分为2组,治疗组80例采用以左氧氟沙星为基础的三联疗法,对照组采用标准三联疗法,停药4周后进行13C呼气试验,统计幽门螺旋杆菌根除率,并同时记录患者不良反应情况。结果治疗组幽门螺旋杆菌根除率为90%,幽门螺旋杆菌根除率为68.8%,差异有显著性(P<0.05)。治疗组药物不良反应发生为率8.75%,对照组药物不良反应发生为率12.29%,无统计学差异(P>0.05)。结论对于幽门螺旋杆菌感染患者,以左氧氟沙星为基础的三联疗法,幽门螺旋杆菌的清除率明显优于标准三联疗法,而药物不良反应率相当,值得临床推广。

To observe the levofloxacin-based triple therapy in eradication of Helicobacter pylori treatment. Methods 202 cases of H. pylori infection were randomly divided into two groups, treatment group of 80 patients with the levofloxacin-based triple therapy, standard triple therapy group, 4 weeks after stopping the C13 breath test, Statistics Helicobacter pylori eradication rate, and patients with adverse reactions were recorded. Results H. pylori eradication rate was 90%, H. pylori eradication rate was 68.8%, the difference was significant （P〈 0.05）. Treatment group as the rate of adverse drug reactions 8.75%, control group rate of adverse drug reactions to 12.29%, no significant difference （P〉 0.05）. Conclusion For H. pylori infection in patients with levofloxacinbased triple therapy, Helicobacter pylori clearance was significantly better than the standard triple therapy, and adverse drug reaction rate is very worthy of clinical